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In the paper “HDAC8, a Potential Therapeutic
Target, Regulates Proliferation and Differentia-
tion of Bone Marrow Stromal Cells in Fibrous
Dysplasia” [1], the authors fuse three elements
of interest. First, and central, is the disease
addressed: fibrous dysplasia (FD), a rare
genetic condition associated with human bone
marrow stromal cells (BMSCs), a population of
adult stem cells whose specific biology and
translational potential make the second ele-
ment of interest in the story. Third, is the epi-
genetic component: the indication of histone
deacetylase 8 (HDCA8), a zinc-dependent HDAC
subtype, as potential therapeutic target for FD.
FD (OMIM#174800) is a rare postnatal dis-
ease linked to somatic mutations in the GNAS
locus, modifying the encoded Gs-α product at
residue 201, prevalently with R201C or R201H
amino acidic substitutions [2]. These mutations
convert the α subunit of the stimulatory G pro-
tein into a constitutively active engine, leading
cells to overproduce cAMP, a central player in
cell metabolism. Although the biochemistry of
Gs-α mutations was dissected more than
15 years ago [3, 4], FD molecular pathophysiol-
ogy is not yet fully defined. However, histologi-
cal features of FD tissues are well-known,
including bone with abnormal trabecular pat-
tern, osteomalacia, enhanced resorption, and
marrow fibrosis, which results from accumula-
tion of osteogenic precursors, loss of adipocytes
and hematopoiesis, and altered vascularity [2].
The contribution of bone marrow to the
pathological process points to FD as a disease of
the bone/bone marrow organ, in which context
BMSCs play a pivotal role. Key experimental evi-
dence of this principle came from the analysis of
ectopic ossicles generated in mice implanted
with FD patients’ BMSCs or exogenously engi-
neered, GNASR201C expressing, BMSCs [5, 6]. In
both cases, it was demonstrated how bone and
bone marrow alterations were detectable in the
chimeric human/mouse organs generated
in vivo. These data imply that the use of BMSCs
is determinant for understanding FD, and for
designing and testing innovative therapeutic
strategies, but also suggest that FD studies are
helpful for dissecting the role played by this
adult stem cell population in the physiology of
bone/bone marrow relationships. This concept
makes FD one—among many—paradigmatic
example underlying how science is synergic and
interrelated in the advancement of knowledge,
beyond boundaries established between applied
and basic research.
Current FD therapies are not yet cures. FD
patients, whose clinical symptoms can be highly
invalidating, are treated with surgical interven-
tions and with drugs controlling bone metabo-
lism, such as bisphosphonates, derivatives of
inorganic pyrophosphate, largely used for oste-
oporotic conditions. In the more recent years,
antibodies have been investigated for treating
FD. This approach has created new hopes, also
based on the high success rate of immunother-
apies for other diseases. A candidate route for
FD therapy is based on the use of anti-RANKL
humanized antibodies, as the Food and Drug
Administration (FDA) approved Denosumab.
RANKL is a key mediator in the response of
bone cells to osteoclast precursors, is highly
expressed in FD patient samples and in BMSCs
expressing the GNASR201C mutation, which
suggests a molecular explanation for excessive
FD bone resorption along with pointing to this
molecule as druggable target [5]. Other molecu-
lar approaches are also being investigated,
albeit directed toward more generalized effects
observed in FD, as the inhibitor of IL-6, Tocilizu-
mab, which targets a disease-induced inflam-
matory condition paralleling strategies applied
to rheumatoid arthritis.
Xiao et al. suggest another route for inter-
vention on FD, based on the exploitation of
epigenetic manipulation of cell metabolism via
HDAC8 inhibitors [1]. HDACs control global
chromatin organization and gene expression,
contributing to multiple biological pathways
and affecting numerous disease conditions
including cancer, autoimmune diseases and
neurodegenerative conditions. HDACs have
robustly entered into the panoply of disease
treatments. Clinicaltrials.com lists 653 studies
based on histone deacetylases, mainly addres-
sing cancer, but also targeting bone conditions.
HDCA8 is a zinc-dependent class I, ubiquitously
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expressed deacetylase, which affects multiple substrates and
regulates diverse physiological and pathological processes [7].
Importantly for the FD setting, HDAC8 impinges on BMSCs
osteogenic differentiation. Xiao et al. show that HDAC8 inhibi-
tion alters FD disease properties, by acting on the cAMP
related cell phenotype and promoting osteogenesis in vivo [1].
Beyond this study, the implementation of epigenetic therapies
for FD has solid bases in the fact that the differentiation prop-
erties and the related epigenetic status of FD BMSCs are pro-
foundly implicated in the disease, since FD mutations, by
inducing overproduction of cAMP, directly impact on cAMP
responsive elements (CRE) and related transcription control by
CRE binding proteins [8].
As outlined above, current strategies for FD include multi-
ple treatments to control or rescue mutation consequences,
including the use of bone metabolism affecting drugs, and
approaches targeting single molecular interactions as in the
case of anti-RANKL antibodies, or multiple molecular events as
with HDAC8 inhibitors. However, the overview of current FD
therapeutic options would not be complete if not integrated
with the concept of tissue engineering approaches based on
BMSCs. Genetic or metabolic correction of autologous FD
BMSCs along with heterologous wild-type bone progenitors
can be used to create bone grafts with potential dominant
positive effects on clinical FD phenotypes. To this goal ex vivo
or in vivo genetic manipulation of BMSCs is particularly rele-
vant. Xiao et al. demonstrate that they can use vectors to
inhibit HDAC8 overproduction observed in FD cells by expres-
sing RNA interfering encoded sequences [1]. We used RNA
interference to correct FD BMSCs identifying allele specific
sequences targeting the GNASR01C mutation [5]. Furthermore,
evolution of these concepts will be the use in FD of CrisprCas
genome editing for in situ disease mutation correction [9].
If therapies for human diseases have always to be evalu-
ated as a success versus risk ratio, there are some important
caveat linked to the specific elements highlighted above. These
include off targets effect of epigenetic manipulation. HDACs
affect the epigenome at large impinging in unpredictable ways
on the overall organismal biology. However, highly targeted,
disease correction frontier tools require precaution too. Crispr-
Cas technology, for example, is dealing with undesired editing
and off target mutations [9]. Lastly, but certainly not least,
perils in tissue engineering strategies involving BMSCs are also
to be taken into account. Although the regeneration potential
of adult stem cell is robustly assessed, the specific nature of
cells possessing this potential, purification protocols, tissues
into which cells can differentiate, are elements complexity [10].
Latest data show that there is a fine developmental hierarchy
in adult stem cell progenitors generating bone, with the most
up to date phenotype identifiable via differential expression of
PDPN, CD146, CD73, and CD164 markers [11]. Usage of BMSCs
for clinical application (or of mesenchymal stem cells) requires
strict purification protocols and full marker phenotyping. Along
with this, such experimental therapeutic strategies need sys-
tematic assessment of efficacy and safety in preclinical settings,
as human ossicles described by Xiao et al., but also animal
models, now available for FD [12, 13].
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